Silverman M, Ilardi C, Bank S, Kranz V, Lendvai S
Division of Gastroenterology, Long Island Jewish Medical Center, New Hyde Park, New York.
Gastroenterology. 1989 Jan;96(1):186-92. doi: 10.1016/0016-5085(89)90779-8.
The effects of the cholecystokinin receptor antagonist L-364,718 was studied in a model of mild pancreatitis induced in mice by repeated injections of the secretagogue caerulein and in a lethal form of pancreatitis induced by feeding mice an ethionine-supplemented choline-deficient diet. L-364,718 prevented the caerulein-induced rise in serum amylase and pancreatic weight in a dose-dependent manner, the most effective dose being 0.1 mg/kg body wt. L-364,718 also prevented the caerulein-induced pancreatic inflammation as seen by light microscopy. L-364,718 offered no protective effects as determined by changes in serum amylase, pancreatic weight, histology, or mortality in the ethionine-supplemented choline-deficient diet model.
在通过反复注射促分泌素蛙皮素诱导小鼠产生轻度胰腺炎的模型以及通过给小鼠喂食补充乙硫氨酸的胆碱缺乏饮食诱导的致死性胰腺炎模型中，研究了胆囊收缩素受体拮抗剂L-364,718的作用。L-364,718以剂量依赖的方式阻止了蛙皮素诱导的血清淀粉酶升高和胰腺重量增加，最有效剂量为0.1mg/kg体重。通过光学显微镜观察，L-364,718还阻止了蛙皮素诱导的胰腺炎症。在补充乙硫氨酸的胆碱缺乏饮食模型中，根据血清淀粉酶、胰腺重量、组织学或死亡率的变化确定，L-364,718没有提供保护作用。
